VBI Vaccines, Inc. (NASDAQ:VBIV) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,386,251 shares, a growth of 163.4% from the June 15th total of 526,262 shares. Approximately 8.3% of the company’s shares are short sold. Based on an average daily volume of 303,618 shares, the short-interest ratio is presently 4.6 days.
Several equities research analysts recently commented on VBIV shares. Noble Financial reissued a “buy” rating on shares of VBI Vaccines in a research note on Friday, May 5th. Zacks Investment Research raised shares of VBI Vaccines from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Saturday, May 6th. TheStreet lowered shares of VBI Vaccines from a “c-” rating to a “d+” rating in a research note on Wednesday, May 31st. Finally, ValuEngine raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Two equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. VBI Vaccines presently has a consensus rating of “Hold” and a consensus target price of $5.38.
Hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. acquired a new position in shares of VBI Vaccines during the second quarter valued at about $187,000. Bank of New York Mellon Corp acquired a new position in shares of VBI Vaccines during the second quarter valued at about $193,000. Bank of Montreal Can boosted its position in shares of VBI Vaccines by 8.6% in the second quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 5,000 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of VBI Vaccines during the first quarter valued at about $383,000. Finally, EAM Investors LLC purchased a new stake in VBI Vaccines during the first quarter worth $414,000. Institutional investors own 29.21% of the company’s stock.
Shares of VBI Vaccines (NASDAQ VBIV) opened at 3.99 on Tuesday. VBI Vaccines has a 1-year low of $2.75 and a 1-year high of $6.60. The company’s 50-day moving average is $4.51 and its 200 day moving average is $4.60. The company’s market cap is $160.51 million.
TRADEMARK VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/08/vbi-vaccines-inc-nasdaqvbiv-short-interest-update-updated-updated.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
